LianBio (LIANY)

OTCMKTS · Delayed Price · Currency is USD
0.1101
+0.0001 (0.09%)
May 21, 2026, 9:30 AM EST
Market Cap11.91M -56.4%
Revenue (ttm)n/a
Net Income-87.98M
EPS-0.82
Shares Out108.17M
PE Ration/a
Forward PEn/a
Dividend0.38 (345.14%)
Ex-Dividend DateJul 15, 2025
Volumen/a
Average Volume21,867
Open0.1101
Previous Close0.1100
Day's Range0.1101 - 0.1101
52-Week Range0.0300 - 0.4394
Beta-0.02
RSI45.07
Earnings DateMay 27, 2026

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 163
Stock Exchange OTCMKTS
Ticker Symbol LIANY
Full Company Profile

Financial Performance

Financial Statements